ImmunityBio, Inc. 8-K

What Happened

• ImmunityBio, Inc. filed an 8‑K (dated June 10, 2026) reporting the results of its June 9, 2026 Annual Meeting of Stockholders. A quorum was present: 885,167,059 of 1,047,345,861 outstanding shares (≈85%) were represented in person or by proxy.
• All nine director nominees were re‑elected to one‑year terms expiring at the 2027 annual meeting. Broker non‑votes totaled 151,521,174 across the director elections. The company’s stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Total outstanding Common Stock (as of April 13, 2026): 1,047,345,861 shares; shares represented at the meeting: 885,167,059 (≈85%).
• Nine directors re‑elected; "For" votes ranged from 714,631,732 to 732,149,734 per nominee; broker non‑votes of 151,521,174 applied to those elections.
• Deloitte & Touche LLP ratified as auditor: 882,420,139 votes "For", 1,675,960 "Against", 1,070,960 abstentions.

Why It Matters

• Corporate governance continuity: re‑election of the full slate of directors maintains the current board and leadership oversight through the 2027 annual meeting, which can be relevant to strategic direction and management continuity.
• Auditor confirmation: ratification of Deloitte as the independent registered public accounting firm establishes who will audit ImmunityBio’s financial statements for FY2026, an important factor for financial reporting and investor confidence.
• High shareholder participation (≈85%) indicates significant investor engagement on these governance matters.